CoV-2 specific serological diagnostics based on epitopes (EpiCoV2020)
- Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
- Total publications:1 publications
Grant number: 01KI20201
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$675,481.56Funder
Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)Principal Investigator
Dr. Michael SzardeningsResearch Location
GermanyLead Research Institution
Fraunhofer Gesellschaft e.V., LeipzigResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The challenge for immune diagnostics dealing with Corona viruses like SARS-CoV-2 is the high background of infections with many different types from this subfamily of Orthocoronavirinae. This project aims at rapidly identifying individual peptide epitopes, both specific and unspecific, and mimotopes with improved affinities for serum antibodies from different patients. We are using resources readily set up for projects similar by the immunological and diagnostic challenge as well as readily available sera from a clinical partner. The project's goal is not only to identify a pool of such epitope/mimotope sequences with a proprietary statistical phage display method, NGS and a specially developed software, but also to rapidly validate them in arrays and in a second step in simple PoC devices to identify those suitable for diagnostic tools. They will differentiate between SARS-CoV-2 and other Corona virus infections, even if the antibody titers are decreasing after the infection. Peptide diagnostics can be reproducibly produced by any peptide manufacturer around the globe. This would contribute to worldwide standards in COVID-19 diagnosis and identification of persons with acquired immunity against the virus. In a more advanced setting differential epitope diagnostics will allow to correlate B-cell response with disease progression in a heterogenous background of recent Corona infections. Cytokine storm monitoring in some patients as well as vaccine development will require these tools. We expect first useful results already about 8 weeks after starting the project.
Publicationslinked via Europe PMC
Last Updated:5 days ago
View all publications at Europe PMC